Clinical Trials Using Testosterone Cypionate

Clinical trials are research studies that involve people. The clinical trials on this list are studying Testosterone Cypionate. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-5 of 5
  • Testosterone Replacement in Male Cancer Survivors With Fatigue and Low Testosterone

    The overall goal of this study is to evaluate the effect of a testosterone drug called Depo-Testosterone (or 'testosterone cypionate'), an FDA-approved drug for improving fatigue, sexual function, quality of life, body composition, muscle strength, and physical activity in young cancer survivors who report fatigue and have low testosterone. Main hypothesis is that Testosterone administration in young male cancer survivors who are in remission for at least 1 year, report cancer-related fatigue and have symptomatic testosterone deficiency will be associated with greater improvements in fatigue scores compared with placebo.
    Location: 2 locations

  • Testosterone Therapy Followed by Enzalutamide or Abiraterone Acetate in Treating Patients with Prostate Cancer That Is Progressing on Combined Androgen Therapies

    This phase II trial studies how well testosterone therapy followed by enzalutamide or abiraterone acetate works in treating patients with prostate cancer that has become worse or spread on combined androgen therapies. Androgens, such as testosterone, can cause the growth of prostate cancer cells. Androgen therapies, such as enzalutamide and abiraterone acetate, suppress or block the production or action of testosterone. Rapid treatment with testosterone may make the cancer cells become sensitive to retreatment with enzalutamide or abiraterone acetate. Giving testosterone prior to enzalutamide or abiraterone acetate may have an effect on the growth of prostate cancer in men who have not responded to long term therapy to lower testosterone in their blood (castrating therapy).
    Location: 2 locations

  • Testosterone and Olaparib in Treating Patients with Castration-Resistant Prostate Cancer

    This phase II trial studies how well testosterone (enanthate or cypionate) and olaparib work in treating patients with prostate cancer that has progressed despite hormonal therapy. Hormonal therapy, such as leuprolide, may lessen the amount of male sex hormones made by the body. In patients that have developed progressive cancer in spite of standard hormonal treatment (i.e. castration-resistant prostate cancer), administering testosterone may result in regression of tumors by causing DNA damage in cancer cells that have adapted to low testosterone conditions. Olaparib may stop the growth of tumor cells by blocking some of the enzymes involved in repairing DNA damage. Therefore, giving testosterone and olaparib together may work better in treating castration-resistant prostate cancer by generating DNA damage that the cancer cell is unable to repair.
    Location: Fred Hutch / University of Washington Cancer Consortium, Seattle, Washington

  • Standard Chemotherapy and Donor Bone Marrow Transplant after Chemotherapy in Treating Patients with Metastatic Castration-Resistant Prostate Cancer

    This pilot phase I clinical trial studies how well donor bone marrow transplant works when given together with standard chemotherapy in treating patients with castration-resistant prostate cancer that has spread to other places in the body. Drugs used in chemotherapy, such as fludarabine and cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving standard chemotherapy and donor bone marrow transplant may work better in treating patients with castration-resistant prostate cancer.
    Location: Johns Hopkins University / Sidney Kimmel Cancer Center, Baltimore, Maryland

  • Testosterone Replacement Therapy in Improving Quality of Life in Prostate Cancer Survivors with Androgen Deficiency

    This phase II trial studies the side effects of testosterone replacement therapy with testosterone cypionate and to see how well it works in improving the quality of life in prostate cancer survivors with androgen deficiency. Testosterone replacement therapy may improve sexual function, health related quality of life, muscle mass, and muscle strength in prostate cancer survivors.
    Location: 4 locations